Literature DB >> 6190310

Changes in the antigenicity of the hemagglutinin molecule of H3 influenza virus at acidic pH.

R G Webster, L E Brown, D C Jackson.   

Abstract

In order to determine the location and biological significance of the acid-induced conformational change in influenza virus hemagglutinin (HA) reported by Skehel et al., monoclonal antibodies were prepared to the molecule before and after treatment at pH 5.0. These antibodies together with monoclonal antibodies to the different antigenic regions of the H3 HA were used in immunoprecipitation and ELISA binding studies to show that antigenic changes accompanied the conformational change in the HA. Treatment at pH 5.2 or less exposed new determinants on the HA while two antigenic regions, located at the tip and interface of the molecule at neutral pH, were lost or modified. Antigenic sites in the loop and hinge regions defined by the available monoclonal antibodies were not affected by the conformational change. Monoclonal antibodies specific for the acid-induced conformation efficiently inhibited hemagglutination of the virus at low pH but were extremely poor inhibitors of virus-induced red blood cell hemolysis at its pH optimum of 5.1. These antibodies were unable to neutralize viral infectivity under neutral or acidic conditions. Antibodies specific for the non-acid-treated HA conformation failed to inhibit hemagglutination at low pH values but were able to both inhibit hemolysis of red blood cells and neutralize virus infectivity. Residual unmodified HA after pH 5.0 treatment could explain the inhibition of hemolysis and infectivity by monoclonal antibodies in each of the different antigenic areas.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190310     DOI: 10.1016/s0042-6822(83)80015-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Protonation and stability of the globular domain of influenza virus hemagglutinin.

Authors:  Qiang Huang; Robert Opitz; Ernst-Walter Knapp; Andreas Herrmann
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

2.  Investigation of pathways for the low-pH conformational transition in influenza hemagglutinin.

Authors:  M Madhusoodanan; Themis Lazaridis
Journal:  Biophys J       Date:  2003-03       Impact factor: 4.033

3.  Activation of fusion by the SER virus F protein: a low-pH-dependent paramyxovirus entry process.

Authors:  Shaguna Seth; Annelet Vincent; R W Compans
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 4.  Insights into neutralization of animal viruses gained from study of influenza virus.

Authors:  M C Outlaw; N J Dimmock
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

Review 5.  Membrane fusion of enveloped viruses: especially a matter of proteins.

Authors:  D Hoekstra
Journal:  J Bioenerg Biomembr       Date:  1990-04       Impact factor: 2.945

6.  Intermonomer disulfide bonds impair the fusion activity of influenza virus hemagglutinin.

Authors:  G W Kemble; D L Bodian; J Rosé; I A Wilson; J M White
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin.

Authors:  L E Brown; J M Murray; D O White; D C Jackson
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

8.  Is bivalent binding of monoclonal antibodies to different antigenic areas on the hemagglutinin of influenza virus required for neutralization of viral infectivity?

Authors:  S Yoden; H Kida; R Yanagawa
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

9.  Monoclonal antibodies detect different forms of influenza virus hemagglutinin during viral penetration and biosynthesis.

Authors:  T Bächi; W Gerhard; J W Yewdell
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

10.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.